Novacyt Deals Itself an Illumina Card — Now It Has to Prove the Cash Lasts

For two years, Novacyt has told a cost-cutting story. This half, management wants you to hear a growth story — and for the first time it has a marquee name to hang it on. H1 revenue rose to £11.6 million, roughly 18% higher year on year, the third consecutive half of sequential growth since £9.6 million in H2 2024. Strip out the newly acquired Southern Cross Diagnostics and the core business still grew about 9%. All three regions grew for the first time in several periods; instrumentation jumped over 30%. That is a different company from the one that spent 2023–24 rationalizing and shuttering sites.

The genuinely new card: Illumina

The freshest theme in the transcript is the five-year Master Collaboration Agreement with Illumina — one of the world's largest sequencing companies. This is not a recycled talking point. Scanning the prior calls, it simply wasn't there a quarter ago; now it tops the company's keyword set, with statement of work and "future content" clustered right beside it. The first SOW is already underway.

This is an agreement for a 5-year period, which I really think is a nod to the confidence in the industry on the longevity of our organization, but also the skill set of our organization.

Read the substance beneath the press-release cadence. Lyn Rees frames it as "commercializing our technical skill sets, specifically in R&D and operations" — in other words, turning Novacyt's content-development muscle into contract work alongside the very sequencing platform its assays already run on. He is careful to say the partnership is for future content, not existing Yourgene-branded products, so it does not magically lower the cost of today's tests. Still, a funded blue-chip workstream is exactly the kind of validation a sub-scale diagnostics name lacks, and it cleanly derisks the pipeline in a market where regulatory routes now take 18 months rather than six.

The tension: a shrinking bank balance

Everything optimistic runs into the cash line. Novacyt consumed about £10 million in H1, £5 million of it on the all-cash acquisition of Southern Cross, and closed June with just under £9 million before drifting to roughly £7.5 million by end-August. Management answers the obvious bear question with unusual bluntness.

The cash burn concern is not new — it dominated the May call and sits high in the company's momentum history for Q1. What has changed is the tone. Three months ago, Rees was on the defensive about a share price "hitting lows" and promised more investor visibility; today the same management declares the burn will fall "materially" once restructuring lands, and points to “just under GBP 9 million in the bank following the all-cash acquisition of Southern Cross. And the important thing remains that we remain debt free.” — Steve Gibson, Chief Financial Officer · 2026-09-30 Debt-free is genuine, and the firepower was real — but a £7.5 million balance against a business still losing £3.9 million of EBITDA a half does not leave much room for a stumble.

The margin problem nobody should skip

The quieter story in the numbers is gross margin, down about 10 percentage points to 56%. Three drivers, only one of them structural: Southern Cross sells at a distributor's ~40% margin (about 3pp dilution), the acquisition's fair-value inventory step-up inflates cost of goods until roughly £0.5 million unwinds through 2026, and the ultra-high-margin Primerdesign RUO revenue base declined as a share of the mix. Steve Gibson is explicit that the last two are not permanent and that management still targets "over 60%" longer term. Investors should hold them to it, because the £4 million restructuring is the other half of the earnings bridge — roughly £2.7 million of labour savings already out the door with ~60 heads gone, plus £0.5–0.7 million of non-labour cuts, for a total of £3.2–3.4 million that mostly hits 2027, not 2026.

The new-product lever is the DPYD assay, now IVDR-approved, pitched as the most complete DPYD test on the market — 19 variants — for patients on 5-FU chemotherapy. The company claims it could save lives in roughly 1 in 100 treated patients. It is a compelling science story, but a small revenue line; the near-term economics still rest on Southern Cross and on reversing the RUO decline.

What management went quiet about

As much as what is said, watch what is dropped. The DHSC dispute — a multi-quarter staple that once swung the narrative by £7 million — does not appear at all this quarter. The Middle East / geopolitical commentary from Q2 is gone. And the long-running defense contract and food-security flirtation, which shareholders pushed management on in May, is quietly settled: “we have no plans to go into that side of the market.” — Lyn Rees, CEO · 2026-05-01 That is a clarifying negative. Novacyt is choosing narrow and funded over speculative and broad — the right call for a company this size, and consistent with the repeated clear focus language that now anchors the pitch.

So where does that leave the bull and bear cases? The bull gets a real, company-unique catalyst (acquisition of Southern Cross adding Asia-Pac reach plus Illumina) and three halves of growth. The bear keeps a thin balance sheet, a dilutive margin mix, and a restructuring whose payoff is a year away. The most telling line is still Rees closing with the same frustration he voiced in May — that the company keeps "delivering on our promises" while the market refuses to re-rate it. The Illumina agreement is the first asset that could genuinely force that re-rating if the funded work scales. Until then, Novacyt remains a demonstration of the widest gap in small-cap healthcare: a story improving faster than the balance sheet can comfortably guarantee.